To Name :
To Email :
From Name :
From Email :
Comments :


Target symptoms, not studies

Vol. 6, No. 5 / May 2007

I will go further than Dr. Nasrallah’s editorial did to endorse off-label use. Our diagnostic categories are 19th century superstitions. Only individual target symptoms have concrete reality. FDA approval studies have parametric statistics based on the bell-shaped curve. These studies represent the population at large. The consecutive series of single-case, on-off experiments have nonparametric distributions. These FDA parametric studies have no relevance to individual care. The FDA serves as a screening tool for potentially useful medications. When applied to individual patients, FDA approval studies are irresponsible, garbage science.

HMO or clinician prescribing that is limited to FDA-approved drugs represents gross malpractice. A better indicator of the standard of care is clinician prescribing patterns recorded by prescription databases. Any use of medication by more than 10% of clinicians at least is a minority standard of care.

Physicians are motivated by patient success. Repeat and widespread prescription is the best indicator of clinical validity.

David Behar, MD
Bethlehem, PA

Did you miss this content?
Botulinum toxin for depression? An idea that’s raising some eyebrows